文献速递心境障碍

CYP2D6与CYP2C19基因型与文拉法辛治疗失败的关联:挪威与英国双队列回顾性研究

Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK.
PubMed 文献 · Lancet Psychiatry · 2026-01-01

该回顾性观察研究纳入挪威精神药理学中心5443例和英国生物银行3624例接受文拉法辛治疗者,按CYP2D6与CYP2C19基因型预测代谢表型分层。结果显示CYP2D6慢代谢型与文拉法辛治疗失败风险升高 consistently 相关,双慢代谢型风险更高,提示预先基因分型可能有助于个体化治疗。

要点

  • CYP2D6慢代谢型者文拉法辛治疗失败风险在挪威与英国队列中均升高。
  • 挪威队列中CYP2D6中间代谢型和超快代谢型换药风险亦升高。
  • CYP2C19慢代谢型可放大CYP2D6慢代谢型的治疗失败风险。

核心结论

  • CYP2D6慢代谢型状态在两个大型真实世界队列中与文拉法辛治疗失败风险增加相关。
  • 预先进行CYP2D6基因分型可能有助于实现文拉法辛个体化治疗。

研究设计与样本

  • 回顾性观察研究,纳入挪威精神药理学中心和英国生物银行两个独立自然队列。
  • 挪威队列5443例接受文拉法辛治疗并完成CYP2D6和CYP2C19基因分型者,英国队列3624例有处方数据者。
  • 排除末次治疗药物监测时合用强CYP2D6或CYP2C19抑制剂或CYP诱导剂者。
  • 按基因型预测代谢表型分为慢代谢型、中间代谢型、正常代谢型和超快代谢型。
  • 主要结局为末次暴露后1年内从文拉法辛换用其他抗抑郁药的治疗失败。

临床怎么用

  • 对计划使用文拉法辛的患者,可考虑预先进行CYP2D6基因分型以识别治疗失败高风险者。
  • CYP2D6慢代谢型尤其合并CYP2C19慢代谢型者,需更密切监测疗效与换药风险。
  • 基因分型结果应结合临床评估用于个体化选择抗抑郁药,而非单独决定治疗。

局限性

  • 为回顾性观察设计,无法确立因果关系。
  • 两个队列均为自然队列,可能存在未测量的混杂因素。
  • 英国生物银行队列仅部分分析CYP2D6慢代谢型,CYP2C19结果主要来自挪威队列。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venlafaxine shows superior efficacy over SSRIs in treating major depression. Metabolism of venlafaxine is mediated by CYP2D6 with a secondary role of CYP2C19. The activity of both enzymes is determined by pharmacogenetic variability, which might affect therapeutic response to venlafaxine. We aimed to investigate associations between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure. METHODS: This retrospective, observational study included two independent, naturalistic cohorts of individuals treated with venlafaxine from the Center for Psychopharmacology (Oslo, Norway) and the UK Biobank. Participants were excluded if they were comedicated with strong CYP2D6 or CYP2C19 inhibitors (ie, bupropion, fluoxetine, paroxetine, fluvoxamine, or levomepromazine) or CYP inducers (ie, carbamazepine, phenobarbital, or phenytoin) at their last venlafaxine therapeutic drug monitoring measurement. Participants were stratified into genotype-predicted poor metabolisers (PMs), intermediate metabolisers (IMs), normal metabolisers (NMs), and ultra-rapid metabolisers (UMs). The primary outcome was treatment failure defined as switching away from venlafaxine to another antidepressant within 1 year after last exposure. People with lived experience did not contribute to the design and writing of this study. FINDINGS: Between Jan 1, 2005, and Dec 15, 2025, 5443 participants genotyped for CYP2D6 and CYP2C19 (3315 [60·9%] women, 2128 [39·1%] men; mean age 48·9 years [SD 18·6]) were identified from the Center for Psychopharmacology. 3624 participants (2401 [66·3%] women, 1223 [33·7%] men; mean age 56·5 years [SD 9·8]) with prescription data were identified from the UK Biobank between 2006 and 2010. In the Norwegian cohort, odds of switching were 2·05 times higher in CYP2D6 PMs (95% CI 1·53-2·71, p<0·0001), 1·25 times higher in IMs (1·05-1·50, p=0·014), and 1·78 times higher in UMs (1·06-2·83, p=0·021) compared with NMs. Increased odds of switching in CYP2D6 PMs were also shown in the UK Biobank cohort (odds ratio 1·58 [95% CI 1·14-2·19], p=0·0060). CYP2C19 PM status amplified risk of failure in the Norwegian cohort with 6·11 times higher odds of switching in dual PMs versus NMs (95% CI 1·81-18·77, p=0·0019). INTERPRETATION: CYP2D6 PM status was consistently associated with increased risk of venlafaxine treatment failure in two large, real-life cohorts, suggesting that pre-emptive genotyping could facilitate personalised venlafaxine therapy. FUNDING: European Research Council, Swedish Research Council, Novo Nordisk Foundation, Robert Bosch Foundation, National Research Foundation of Korea, and the South-Eastern Norway Regional Health Authority.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Park Y, Lenk HÇ, Zhou Y, et al. Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK. Lancet Psychiatry. 2026. PMID: 42716055. doi:10.1016/S2215-0366(26)00238-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。